Year: 2021

Accepted Abstracts Include Real-World Experience with Oxbryta® (voxelotor) and Phase 1 Data on GBT021601 and Inclacumab SOUTH SAN FRANCISCO, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) — Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that six abstracts related to its sickle cell disease (SCD) programs, including data from the growing body of real-world evidence on Oxbryta® (voxelotor) tablets and new data on GBT’s pipeline, will be presented at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition. The meeting is taking place online and in person at the Georgia World Congress Center in Atlanta, Georgia from December 11-14, 2021. “Our data presentations at ASH 2021 include three new analyses from the growing body of data on Oxbryta that reinforce our belief in the benefits of this innovative...

A poster presentation featuring preclinical data on AFM28, a novel Innate Cell Engager developed for treatment of Acute Myeloid Leukemia and other CD123+ myeloid malignancies A poster presentation on AFM13 precomplexed NK cells that maintained biological activity and potency after one cycle of freezing, resulting in a cryopreserved, off-the-shelf CAR-like NK cell therapy A company sponsored investor event in mid-December to provide a clinical development update on AFM13HEIDELBERG, Germany, Nov. 04, 2021 (GLOBE NEWSWIRE) — Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that it will present two posters on its innate cell engagers (ICE®) at the 63rd American Society of Hematology Annual Meeting and Exposition (ASH). Details...

Lund, November 4, 2021 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that two abstracts with new preclinical data on tasquinimod, a small molecule immunomodulator, have been accepted for presentation at the 63rd ASH Annual Meeting & Exposition in Atlanta, Georgia, December 11-14, 2021. The results that will be highlighted in the poster presentations are part of Active Biotech’s program to address the unmet medical needs to treat hematological malignances, with focus on multiple myeloma. Currently, a clinical phase Ib/IIa trial in patients with multiple myeloma is ongoing. Information on the presentations: P 1595. Tasquinimod Targets Immunosuppressive Myeloid Cells, Increases Osteogenesis and Has Direct Anti-Myeloma Effects by Inhibiting c-Myc Expression in Vitro and In Vivo. Poster session 651. Multiple Myeloma...

Company announcement – No. 65/ 2021 Zealand Pharma Announces First Subject Dosed in Phase 1 Trial of Amylin Analogue ZP8396 for the Treatment of ObesityPreclinical data have shown potent anti-obesity effects of ZP8396 both as a monotherapy and in combination with a GLP1 analogue.Copenhagen, DK and Boston, MA, U.S. November 4, 2021 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078,) a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, today announced that the first patient has been dosed in a Phase 1 clinical trial evaluating the amylin analogue, ZP8396 as a potential treatment option in obesity. The study is a single ascending, dose-escalation, safety and tolerability trial in healthy volunteers. “ZP8396 holds potential as a novel treatment option for obesity...

With Embedded Listener, Program Accelerator, and updates to the platform’s AI- and ML-powered Insights features, GetFeedback users will create and close feedback loops faster and in new areas of the customer journey SAN MATEO, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) — Momentive (NASDAQ: MNTV—formerly SurveyMonkey), a leader in agile experience management, today announced the availability of new GetFeedback capabilities that empower users to create and close feedback loops faster, allowing CX leaders to act upon meaningful insights with greater agility. With Embedded Listener, Program Accelerator, and new updates to the AI- and ML-powered Insights capabilities, CX professionals can drive better experiences across the entire customer lifecycle faster, iterate with ease, and deploy without requiring expensive consultants. The new capabilities...

Two abstracts will be presented in a pre-recorded poster presentation and oral session MONT-SAINT-GUIBERT, Belgium, Nov. 04, 2021 (GLOBE NEWSWIRE) — Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that two abstracts have been accepted for a poster presentation and an oral session at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, which will be held in person in Atlanta, Georgia and virtually from December 11-14, 2021. The poster will focus on the Company’s shRNA-based anti-BCMA allogeneic CAR T candidate CYAD-211 for the treatment of relapsed/refractory (r/r) multiple myeloma (r/r MM). The oral session will focus on the Company’s autologous...

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint pathway, today announced the Company will be presenting early clinical data from ASPEN-02, its ongoing Phase 1/2 study evaluating evorpacept in combination with azacitidine for the treatment of myelodysplastic syndromes (“MDS”) in a poster presentation at the 63rd American Society of Hematology (“ASH”) Annual Meeting held December 11-14, 2021 in Atlanta, Georgia. Key Abstract Data As of July 15, 2021, 13 subjects with newly diagnosed (“ND”) higher risk or relapsed/refractory (“R/R”) MDS were enrolled into phase 1 cohorts receiving escalating doses of evorpacept (20 mg/kg Q2W, 30 mg/kg Q2W, and 60 mg/kg Q4W) combined...

LEXINGTON, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) — Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced that four abstracts will be presented from the KER-050 and ALK2 hematology programs, including additional preliminary results from Keros’ Phase 2 clinical trial of KER-050 in patients with very low-, low-, or intermediate-risk myelodysplastic syndromes (“MDS”), at the 63rd American Society of Hematology (“ASH”) Annual Meeting and Exposition, to be held in person and virtually from December 11 through 14, 2021. The following abstracts were posted to the ASH website on November 4, 2021, 9:00 a.m....

LONDON and REDWOOD CITY, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) — Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical stage biopharmaceutical company focused on oncology and rare diseases, today announced that data from an investigator-sponsored study of alvelestat in patients with Bronchiolitis Obliterans Syndrome (“BOS”) following hematopoietic stem cell transplantation (“HCT”) will be shared in a poster presentation at the 2021 American Society of Hematology (ASH) Annual Meeting, being held December 11-14, 2021 in Atlanta, Georgia and virtually. Following are the details of the poster presentation: Title: Effects of Alvelestat, an Oral Neutrophil Elastase Inhibitor, on Elevated Elastase and Collagen Turnover Biomarkers in Patients with Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation Date...

Conference call to be held Thursday, November 11, at 4:30 p.m. Eastern Time ATLANTA, GA, Nov. 04, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — GeoVax Labs, Inc. (Nasdaq: GOVX) (“GeoVax” or the “Company”), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, announces today that it will report third quarter 2021 financial results on Thursday, November 11, 2021 after the market closes. Management will host a conference call at 4:30 p.m. ET on Thursday, November 11, 2021 to review financial results and provide an update on corporate developments.  Following management’s formal remarks, there will be a question-and-answer session. Participants are asked to pre-register for the call via the following link: https://dpregister.com/sreg/10161852/ef8e798f78 Please note that registered...